Smartwatches and other “smart devices” equipped with a wide range of health-related features — from blood-pressure readings to body temperature and blood-oxygen saturation — no longer surprise anyone. But as these devices grow more advanced, so does the risk that people begin treating them like actual medical instruments.
In its latest notice, the FDA stated that the “Blood Pressure Insights” feature offered by WHOOP’s smart bands — although marketed as a lifestyle and wellness tool — meets the criteria for a medical device because it measures values that could be used in diagnosing hypertension. WHOOP had previously rejected such claims, arguing that its data is meant to be indicative, not diagnostic. But the regulator determined that the very ability to monitor blood pressure creates a real risk if users interpret the data as medical information.
Experts say the enforcement action signals that the increasingly blurry line between wellness gadgets and medical devices is now being more strictly regulated. According to the FDA, manufacturers of such gadgets must prepare for clinical testing, quality audits, cybersecurity safeguards, and formal registration filings. This significantly increases costs and extends the time needed to bring products to market.
For major players in the sector — such as Apple or other companies already pursuing medical approvals — the new rules may be challenging, but manageable. However, for smaller firms, startups, or niche “smart band” makers, the requirements pose a serious threat. Many projects may be halted, delayed, or abandoned altogether because of heightened FDA oversight.
If this regulatory direction continues, the wearables sector — long driven by freedom from medical-device procedures and a low barrier to entry — may undergo a major transformation. Analysts warn that innovation in mass-market consumer products could decline, while rising compliance costs may become a significant obstacle for companies with limited resources.
